Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/17/2010

herapy!  As always, we thank you for your support.

Sincerely,

Geert Kersten

Chief Executive Officer

Maximilian de Clara

President

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2009. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For more information, please visit www.cel-sci.com.

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... , July 30, 2015 Takeda Pharmaceutical ... study to fulfill the post-marketing commitment and submissions ... Pan European Multi-Database Bladder Cancer Risk Characterization Study ... cohort study, conducted in four European countries, for ... up to 10 years of follow-up. Findings demonstrate ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
... ... Reportlinker.com announces that a new market research report ... Markets for Breast Biopsy Devices 2009 , ... markets for breast biopsy devices includes the spring ...
... , NATICK, Mass. and LONDON, Nov. ... ) today announced that it has received 510(k) clearance ... CE Mark approval to market its WallFlex® Fully Covered ... (obstructions) caused by tumors in patients with resectable or ...
Cached Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This is ... Dr. Clevens has worked closely with the university, developing a strong presence and a ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... the latest issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, ... of the new issue, Volume 6, Issue 2, as well as past issues ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web Marketing ... Summit. Google Partners is the platform for search marketing agencies to communicate with ... tools necessary to run successful search marketing campaigns. Google Partners also affords businesses ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy ... nonsurgical treatment designed specifically for the elimination of excess tissue under the ... locations in the state of Wisconsin to offer this innovative treatment. , Developed by ...
(Date:7/30/2015)... ... 30, 2015 , ... The American Association of Poison Control ... the reinstitution of National Prescription Drug Take-Back Days. The 10th event of this ... 2:00 PM local time. On the 26th, the DEA, with the assistance of ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3
... ... them , ... 2010 -- Still hunting for the perfect Mother,s Day gift idea? While it,s wonderful to ... universally don,t have enough of is sleep. With Mother,s Day right around the corner on May ...
... ... Assess & Treat the Country’s Pest Management Needs, , ... (PRWEB) April 29, 2010 -- Most people are aware of the ... January 12th. While the country is still dealing with widespread damage to its infrastructure ...
... Geneva, 29 April 2010 -- Lung cancer patients whose tumors ... than those who do not, Canadian researchers have found. Their ... Geneva, highlights the exciting possibility that the molecule could soon ... is a receptor that is found on the surface of ...
... Practicing non-pharmaceutical interventions (NPIs) such as hand-washing and ... pandemic flu, but more research on these measures is ... May issue of AJIC : American Journal ... Association for Professionals in Infection Control and Epidemiology, Inc. ...
... ... errors and boost quality of service , ... Trevose, PA (PRWEB) April 29, 2010 -- Airclic, ... logistics and field service operations, today introduced Clinical Perform, a SaaS-based mobile software product ...
... clumps of protein, not plaques, may cause the disease, ... research could change the way scientists view the causes -- ... A study published online this month in the Annals ... (abeta) proteins called oligomers could be a prime cause of ...
Cached Medicine News:Health News:The Perfect Mother's Day Gift Idea: A Good Night's Sleep 2Health News:Clark Pest Control Executive Asked to Aid Haitian Government with Post-Earthquake Pest Issue 2Health News:Clark Pest Control Executive Asked to Aid Haitian Government with Post-Earthquake Pest Issue 3Health News:CXCR4: A new drug target in lung cancer 2Health News:Hand-washing, mask-wearing may limit transmission of pandemic flu 2Health News:Hand-washing, mask-wearing may limit transmission of pandemic flu 3Health News:Airclic Introduces Clinical Perform™ 2Health News:Airclic Introduces Clinical Perform™ 3Health News:New Finding Could Mark Shift in Alzheimer's Research 2Health News:New Finding Could Mark Shift in Alzheimer's Research 3
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... an X-ray contrast medium for ... for: angiography, urography, phlebography and ... of the basal cisterns, following ... cholangio (pancreato) graphy (ERC(P)), herniography, ...
... (gadobenate dimeglumine) is a paramagnetic MRI contrast ... with gadobenate, a chelating agent that forms ... godolinium ion. It is salified with meglumine ... with all the physico-chemical features typical of ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
Medicine Products: